Introduction
The SELECT-MONOTHERAPY trial showed that upadacitinib (UPA) can be a safe and effective treatment for rheumatoid arthritis patients who didn’t respond well to methotrexate. This report highlights key findings from the 260-week follow-up.
Study Overview
In this study, patients were randomly assigned to continue methotrexate or switch to UPA at doses of 15 mg (UPA15) or 30 mg (UPA30) for 14 weeks. After that, all patients, including those who were on methotrexate, switched to UPA15 for the rest of the study. Safety and efficacy were measured and reported.
Results
Out of 648 patients, 598 stayed in the long-term study. By week 260, 249 patients (about 41.6%) stopped the treatment for various reasons, including side effects and withdrawal. The study found higher rates of some health issues with the UPA30 dosage compared to UPA15.
However, over 39% of patients on UPA continuously achieved significant improvement in their condition, as measured by disease activity scores, indicating that UPA was effective throughout the treatment period.
Conclusion
Long-term use of UPA showed no new safety concerns, and it was effective for rheumatoid arthritis treatment up to week 260.
Measurable Outcomes and Goals
Clinics and patients should aim for clear goals regarding the use of UPA as a standalone treatment. Tracking improvement in disease activity scores can help measure success.
AI Tools for Clinical Needs
Selecting AI tools designed for specific healthcare tasks can enhance patient management based on the research findings of UPA.
Implementation Steps
Start with a pilot program to track patient outcomes using AI solutions. Monitor the real-world impact of UPA treatment over time.
Contact Us for AI Solutions
For more information on AI tools in medical management, reach out to us:
